CStone Pharmaceuticals (HKG:2616)
Hong Kong · Delayed Price · Currency is HKD 6.07
-0.10 (-1.62%)
Sep 10, 2026, 11:59 AM HKT
CStone Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, CStone Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $14.44. The average 1-year stock price forecast is 138.09% higher than the current stock price, while the lowest is $9.86 (+62.57%) and the highest is $20.01 (+229.93%).
Price Target: $14.44 (+138.09%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CStone Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst SDIC Securities No rating | SDIC Securities | Buy Maintains $7.73 | Buy | Maintains | $7.73 | +27.45% | Sep 3, 2026 |
Unknown Analyst Goldman Sachs No rating | Goldman Sachs | Buy Maintains $8.26 → $9.44 | Buy | Maintains | $8.26 → $9.44 | +55.65% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
423.15M
from 269.58M
Increased by 56.97%
Revenue Next Year
1.72B
from 423.15M
Increased by 307.00%
EPS This Year
0.20
EPS Next Year
-0.16
from 0.20
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.